Evidence map›Paper›PMID 36177869›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2022

Use of healthcare reimbursement data to monitor bacterial sexually transmitted infection testing in France, 2006 to 2020.

Delphine Viriot, Etienne Lucas, Bertille de Barbeyrac, Cécile Bébéar, Sébastien Fouéré, Nicolas Dupin, Antoine Bertolotti, Béatrice Berçot, Charles Cazanave, Gilles Delmas and 3 more

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Delphine ViriotSanté publique France (the French National Public Health Agency), Saint-Maurice, France.
Etienne LucasSanté publique France (the French National Public Health Agency), Saint-Maurice, France.
Bertille de BarbeyracFrench National Reference Centre for bacterial STI (Chlamydia, Mycoplasma), Bordeaux University Hospital, Bordeaux, France.
Cécile BébéarFrench National Reference Centre for bacterial STI (Chlamydia, Mycoplasma), Bordeaux University Hospital, Bordeaux, France.
Sébastien FouéréAPHP, Saint-Louis University Hospital, Paris, France.
Nicolas DupinFrench National Reference Centre for bacterial STI (Syphilis), APHP, Cochin University Hospital, Paris, France.
Antoine BertolottiInserm-CIC1410, La Reunion University Hospital, Saint Pierre, Reunion Island, France.
Béatrice BerçotFrench National Reference Centre for bacterial STI (Gonorrhea), APHP, Saint-Louis University Hospital, Paris, France.
Charles CazanaveFrench National Reference Centre for bacterial STI (Chlamydia, Mycoplasma), Bordeaux University Hospital, Bordeaux, France.
Gilles DelmasSanté publique France (the French National Public Health Agency), Saint-Maurice, France.
Josiane PillonelSanté publique France (the French National Public Health Agency), Saint-Maurice, France.
Florence LotSanté publique France (the French National Public Health Agency), Saint-Maurice, France.
Ndeindo Ndeikoundam NgangroSanté publique France (the French National Public Health Agency), Saint-Maurice, France.
Santé Publique France · FRInstitut Polytechnique de Bordeaux · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Saint-Louis · FRInserm · FRInstitut thématique Santé Publique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundDiagnoses of bacterial sexually transmitted infections (STIs) have increased in France since the 2000s. The main strategy to control STI transmission is recommending/facilitating access to condom use, testing, and antibiotic treatments.AimThis study analyses the evolution of STI testing in the private sector in France from 2006 to 2020.MethodsNational health insurance reimbursement data were used to determine numbers and rates of individuals aged ≥ 15 years tested for diagnoses of chlamydia, gonorrhoea and syphilis in the private sector in France and to describe their evolution from 2006 to 2020.ResultsUpward tendencies in testing were observed from 2006 to 2019 for all three STIs. The highest testing rates were identified in people aged 25‒29-years old. The observed testing-increase from 2017 to 2019 was twice as high in young people (< 25 years old) as in older people. In 2019, chlamydia, gonorrhoea and syphilis testing rates were respectively 45.4 (+ 21% since 2017), 41.3 (+ 60%), and 47.2 (+ 22%) per 1,000 inhabitants. For all STIs combined, the number of tested individuals decreased by 37% between March and April 2020 during the first COVID-19 epidemic wave and lockdown in France.ConclusionImprovements found in STI testing rates may have resulted from better awareness, especially among young people and health professionals, of the importance of testing, following prevention campaigns. Nevertheless, testing levels remain insufficient considering increasing diagnoses. In 2020, the COVID-19 pandemic had a considerable impact on STI testing. Partner notification and offering diverse testing opportunities including self-sampling are essential to control STI epidemics particularly in exposed populations.

Indexed as

Chlamydia InfectionsCOVID-19GonorrheaHIV InfectionsSexually Transmitted DiseasesSyphilisAdolescentAdultAgedAnti-Bacterial AgentsCommunicable Disease ControlDelivery of Health CareHumansPandemicsAnti-Bacterial Agentschlamydia infectionCOVID-19 impactgonorrhoeaSTIsyphilistesting

Identifiers

PMID36177869
PMCPMC9524053
OpenAlexW4298087275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.